Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 152Lymphoma, Mantle-Cell 30Lymphoma, Non-Hodgkin 22Lymphoma, Follicular 22Lymphoma 22Recurrence 21Neoplasms, Plasma Cell 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 11Lymphoma, Large B-Cell, Diffuse 11Immunoglobulin Light-chain Amyloidosis 10Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, B-Cell 7Leukemia 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Amyloidosis 5Lymphoma, Large-Cell, Immunoblastic 4Hematologic Diseases 4Congenital Abnormalities 4Prostatic Neoplasms 3Paraproteinemias 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

Cytarabine 26Daunorubicin 11Mitoxantrone 7Idarubicin 7Etoposide 7fludarabine phosphate 6Filgrastim 6Busulfan 6Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Methotrexate 5Gemtuzumab 5Clofarabine 5tipifarnib 4alvocidib 4Vorinostat 4Decitabine 4Azacitidine 4sargramostim 3Whole-Body Irradiation 3Observation 3Mycophenolic Acid 3Granulocyte Colony-Stimulating Factor 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3entinostat 2Sirolimus 2Pravastatin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Acute × Bortezomib × Clear all
NCT00666588 2018-05-22

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 17 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00818649 2017-12-28

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
16 enrolled 7 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00742625 2014-09-12

Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
95 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡